News

Media attention | Yu Qiang: the entrepreneurial path of "veterans" in the pharmaceutical industry

  • Categories:Company News
  • Author:
  • Origin:
  • Time of issue:2022-09-24
  • Views:0

(Summary description)On August 8, the first domestic terifluoramine tablets developed by Shengshi Tyco were put on the market, bringing new choices and drug supply guarantees for domestic patients with multiple sclerosis.

Media attention | Yu Qiang: the entrepreneurial path of "veterans" in the pharmaceutical industry

(Summary description)On August 8, the first domestic terifluoramine tablets developed by Shengshi Tyco were put on the market, bringing new choices and drug supply guarantees for domestic patients with multiple sclerosis.

  • Categories:Company News
  • Author:
  • Origin:
  • Time of issue:2022-09-24
  • Views:0

On August 8, the first domestic terifluoramine tablets developed by CGeneTech were put on the market, bringing new choices and drug supply guarantees for domestic patients with multiple sclerosis.

In this regard, Yu Qiang, founder and CEO of CGeneTech Biomedical Technology (Suzhou) Co., Ltd., was gratified and said that after more than ten years of running, the company finally took the first step in the long march.

In May 2018, multiple sclerosis was included in the first batch of rare diseases in China.

Yu Qiang said that in fact, rare diseases are not rare. But there is no medicine to cure, which is the unspeakable pain of patients with rare diseases. The earlier multiple sclerosis is diagnosed and treated, the better it can relieve symptoms and delay disease development.

CGeneTech was founded in Suzhou Industrial Park in 2010. Its core team has decades of experience in the whole life cycle of international drugs and is committed to the research, development and industrialization of small molecule innovative drugs for breakthrough therapies. Relying on the integrated drug R&D technology platform and diversified business vision, the company has built a rich pipeline of innovative drugs, covering many disease fields such as hypoglycemic, anti-cancer and rare diseases.

Yu Qiang has a solid academic background in the field of chemistry. He has successively obtained bachelor's, master's and doctor's degrees in chemistry from Peking University, Kansas State University to the University of Kansas. After graduation, he worked in the pharmaceutical chemical technology company for many years, and successfully founded a company to develop new drug molecular modules. After nearly 20 years of overseas career, he returned to China in 2010 and co founded CGeneTech with Mr. Ding Juping, who has rich experience in new drug research and development and application.

Yu Qiang has always been accompanied by the three soul questions of "why do you want to return to China to start a business", "why do you want to choose Suzhou to start a business", and "how difficult it is to start a business". He always gives standard answers to the first two, but has no answer to the last one.

Talking about why he returned to China to start a business, Yu Qiang explained: "there are two main reasons. First, around 2008, we found a series of active compounds aimed at DPP-IV, the target of diabetes, and hoped to promote R & D and industrialization as soon as possible. At that time, the domestic support and entrepreneurial environment for returnees, especially the policies on biomedicine, were becoming more and more mature."

In addition, it is Yu Qiang's wish to let domestic patients use affordable good drugs and new drugs, which is also an important factor in his choice to return to China to start his own business. "This is a right choice made at the right time. China is full of changes, opportunities and challenges. I think there is much to be done."

"The decision to come to Suzhou to start a business was convinced by the emails. When I was still in the United States, I asked the Suzhou Industrial Park government about entrepreneurship and received professional replies. I felt that my English was better than mine, which made me curious about Suzhou." When Yu Qiang set foot on the land of Suzhou, he found that Suzhou, where "everyone sleeps on the river", has a strong innovation ability.

Now, Yu Qiang has been dormant on the thorny road of entrepreneurship for more than ten years. He found that in addition to being very livable, Suzhou also provided considerate care and precise services for talents, and was able to take into account various pain points in the growth process of biomedical innovative enterprises, providing a variety of preferential policies.

How difficult is entrepreneurship? Yu Qiang said that this is a question in the present continuous tense and there is no answer. In his own words, this is the "Long March" of China's bio pharmaceutical industry. Once given up, it means that all previous efforts and sacrifices have been wasted.

"2015 has been the hardest year so far." Yu Qiang recalled that when he started his business in China, his income was very low, and it was very difficult for the company to raise funds. He did not have enough money for clinical trials. In 2015, the company had capital problems, and the brain drain was serious. All the people who wanted to recruit did not come to the company when they were offered an offer. That year was really tough.

Many years later, looking back on that period of time, Yu Qiang said that "feelings are a kind of power". He said that the original intention of driving himself to complete this road was to "let domestic patients use affordable good drugs and new drugs. I never thought of giving up. If I gave up, all the efforts ahead, including the sacrifices made by my family, would not be worth it."

"A general's success will wither away." Yu Qiang lamented that many returned scientific researchers in the past, after experiencing the difficulties of entrepreneurship, still fell behind the long cycle of drug research and development, huge investment in research and development, and extremely low success rate of research and development. This is exactly one of the fundamental reasons why VCs were not keen on this field in the past few years. After all, after the investment, they may face long-term problems such as no take-up and blocked exit channels, which obviously means "no money" for institutions. This has made returned entrepreneurs suffer from a shortage of funds.

"I am lucky. As long as I am still running on the road, there is hope." Since his return to China, Tyco has been developing along the path of "me too to me first", and its clinical applications have increased year by year. Up to now, CGeneTech has accumulated nearly 600 million yuan of financing.

Yu Qiang said that he just wanted to take the team to every step. Keep moving forward, do not stay mediocre, let alone fall behind. It feels like a long-distance race. You must hold on to the leader. You must be in the first echelon. In the first echelon, you will have the opportunity to surpass.

Yu Qiang is jokingly called the best poet in the medical field, and the best poet in the poetic field. Drug research and development is like the creation of ancient poetry. Medicine is in poetry, and poetry is in people's hearts. Suzhou has been favored by literati since ancient times, whether it is the landscape of small bridges, flowing water and people's homes, or the exquisite taste of Jiangnan. All this has provided Yu Qiang with spiritual comfort.

                                                                                                                                                      Source: China News Network Author: Zhou Jianlin

Shengshi

Shengshi Taike has been awarded the "Double Yellow Egg" of Jiangsu Province's innovation and entrepreneurship talents

Jiangxiang is near Xiaoman, with warm air and moving grasshoppers. Recently, the selection results of Jiangsu Province's "Double Innovation Plan" for 2024 have been officially announced. Shengshi Taike's talent team has won the "Double Yellow Egg" award: the core team led by Dr. Wang Tong, Chief Scientific Officer, has been successfully selected as the "Double Innovation Team" in Jiangsu Province in 2024, and is the only "Innovation Team" in the field of biomedicine in Suzhou; Dr. Zhao Jiahong, Chief Medical Officer, has been successfully selected as a "Double Innovation Talent" in Jiangsu Province in 2024. The "Double Innovation Plan" in Jiangsu Province mainly focuses on introducing and funding scarce talents in the "high-precision and cutting-edge" and "bottleneck" fields, supporting the development of new technologies in key areas, and is an important brand project for talent work in Jiangsu Province. This plan focuses on the key industries prioritized for development in Jiangsu Province, playing an important role in enhancing independent innovation capabilities, promoting industrial structure optimization and upgrading, and driving rapid economic development. Dr. Wang Tong was just awarded the title of "Double Innovation Talent" in Jiangsu Province last year, and this time he led the company's core team to win the honor of "Double Innovation Team" in Jiangsu Province, fully reflecting the continuous innovation ability of the company's talent team. Dr. Wang Tong, as the Chief Scientific Officer of Shengshi Taike, has over 20 years of experience in the full chain drug research and management of top pharmaceutical companies and research institutes in the United States. He is a strategic scientist who can break through key technologies, drive emerging disciplines, and promote the new drug industry. Since joining Shengshi Taike, I have been awarded the title of leading technology talent at all levels, bringing innovative thinking and advanced technological means to the company. I have integrated and formed a complete new drug development and industrialization platform, leading the company's R&D team to accelerate the development of the new drug product pipeline. One of the core product pipelines, the hypoglycemic drug sengliptin, has been launched for sale. Dr. Zhao Jiahong, a core member of the "Double Creation Team", was also awarded the honor of "Double Creation Talent" in Jiangsu Province this time. Dr. Zhao Jiahong, as the Chief Medical Officer of Shengshi Taike, has over 20 years of experience in drug clinical trials and team management, and is an external expert of CDE; Has rich practical experience in medical affairs and early drug development, clinical development strategies, and international multicenter clinical trials, and has led and participated in over 600 clinical projects; I also have some experience in post market re evaluation of drugs. Since joining Shengshi Taike, I have been fully responsible for the company's new drug clinical development strategy and pathway, as well as post market expansion research and other important tasks. Among the core members of the "Double Creation Team", Dr. Lu Qin graduated from Fudan University with a major in Medical Systems Biology and holds the associate senior professional title. She has achieved fruitful research results in the field of biology, published multiple high-quality papers, obtained nearly 10 authorized invention patents, led the company's biology team to complete multiple project research tasks, and won multiple honors such as leading the park. Dr. Ouyang Zhenwu graduated from the Organic Chemistry Department of the Chinese Academy of Sciences. He has demonstrated outstanding academic and professional achievements in the field of pharmaceutical chemistry. He has published six high-quality papers in internationally renowned chemical journals, demonstrating his profound skills in chemical synthesis and drug design. Since joining the company, Dr. Ouyang has repeatedly used "innovative synthesis methods" to simplify the synthesis route, which not only significantly improves the efficiency of new drug screening, but also saves costs for the company in new drug development. Shengshi Taike, composed of these innovative talent teams, is a biotechnology company in the commercial stage. The core team has decades of experience in the entire lifecycle of international drugs and is committed to the research and industrialization of high-quality and differentiated small molecule innovative drugs. The company has built a rich pipeline of innovative drugs covering hypoglycemic, anticancer, and autoimmune diseases through an integrated drug research and development technology platform and diversified business perspectives.
2025-05-22
Media

Media Attention | Yu Qiang, an "unsmart" entrepreneur, and his new diabetes drug Sengliptin

Qiang Yu, the founder and CEO of CGeneTech, a doctor of chemistry from Peking University, founded a biotechnology company in the United States at the beginning of this century, and later returned to China to found CGeneTech and developed a new type 2 diabetes drug, a new generation of DPP-4 inhibitor senpaglitin, which has now been approved for marketing.
2025-04-16

Contact Us

Add:Room 101, Bld C11, 218 Xinghu Rd,Suzhou industrial Park,China, 215123

Tel: +86-512-62956960(Recruitment)

         +86-512-62956961(marketing)

Copyright © 2022  CGeneTech (Suzhou, China) Co., Ltd.  All rights reserved.  苏ICP备2022006552号-1  Powered by 300.cn  SEO